Verastem Inc
$ 5.90
3.51%
24 Feb - close price
- Market Cap 429,323,000 USD
- Current Price $ 5.90
- High / Low $ 5.99 / 5.66
- Stock P/E N/A
- Book Value -0.23
- EPS -4.28
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.66 %
- ROE -28.89 %
- 52 Week High 11.25
- 52 Week Low 4.01
About
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
Analyst Target Price
$17.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-07 | 2025-05-07 | 2025-03-12 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-03-14 |
| Reported EPS | -1.35 | -0.62 | -0.79 | -0.6 | -0.6 | -0.31 | -1.26 | -1.02 | -0.75 | -1.37 | -0.08 | -0.08 |
| Estimated EPS | -0.87 | -0.88 | -0.775 | -0.7367 | -0.74 | -0.95 | -1 | -0.62 | -0.84 | -1.06 | -0.08 | -0.1 |
| Surprise | -0.48 | 0.26 | -0.015 | 0.1367 | 0.14 | 0.64 | -0.26 | -0.4 | 0.09 | -0.31 | 0 | 0.02 |
| Surprise Percentage | -55.1724% | 29.5455% | -1.9355% | 18.5557% | 18.9189% | 67.3684% | -26% | -64.5161% | 10.7143% | -29.2453% | 0% | 20% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.49 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VSTM
2026-02-20 23:32:06
Verastem Oncology announced positive updated data from a Phase 1/2 trial of GFH375 (VS-7375), their oral KRAS G12D (ON/OFF) inhibitor, conducted by partner GenFleet Therapeutics in China. The study showed an overall response rate (ORR) of 52% in pancreatic ductal adenocarcinoma and 42% in non-small cell lung cancer patients. Verastem plans to initiate a Phase 1/2a trial for VS-7375 in the U.S. and will host an investor webcast to discuss these and other updated data.
2026-02-18 12:27:34
Verastem Oncology (Nasdaq: VSTM) announced it will host a conference call and webcast on Wednesday, March 4, 2026, at 4:30 pm ET to discuss its fourth quarter and full year 2025 financial results and business updates. Interested parties can access the call via phone or a live audio webcast on the company's investor relations website. A replay of the webcast will also be available after the event.
2026-02-16 05:57:51
Verastem has reported strong commercial momentum for its low-grade serous ovarian cancer (LGSOC) therapy, with sales growing over 50% quarter-to-quarter and broad adoption. The company anticipates a readout for its confirmatory RAMP 301 trial around mid-next year and expects mid-year data updates for its pancreatic triplet study RAMP 205 and KRAS G12D inhibitor VS-7375. These pipeline developments and sales performance highlight key catalysts for the biopharmaceutical company.
2026-02-11 20:27:50
Verastem, Inc. (VSTM) is seeing continued strong sales growth and broad adoption for its lead therapy, supported by strong reimbursement and long patient duration. Key clinical trials, including a pivotal confirmatory study and a G12D inhibitor, are progressing well. Major data updates for these trials are anticipated mid-year.
2026-02-09 20:27:38
HC Wainwright has increased its FY2025 EPS estimate for Verastem (NASDAQ:VSTM) to ($3.19) from ($3.21) and maintained a "Buy" rating with an $18 price target. This adjustment comes despite projections of multi-year losses through FY2027, with profitability anticipated by FY2030. Verastem's stock currently trades around $6.67, with high institutional ownership and recent insider selling.
2026-02-08 08:29:18
Verastem, Inc. (NASDAQ:VSTM) has received a consensus "Moderate Buy" rating from ten brokerages, with an average one-year price objective of $15.83. This positive sentiment follows preliminary Q4 and full-year 2025 revenue exceeding expectations, driven by an Avmapki co-pack partnership. Despite some recent insider selling, institutional ownership remains high at 88.37%, with significant recent additions from firms like Squarepoint and Armistice.
